Table 2.
Baseline characteristics of the patients in this study (n = 73), separated by type of MVC therapy
| Parameter | Valuea |
|
|---|---|---|
| MVC monotherapy (n = 48) | MVC add-on therapy (n = 25) | |
| Age (yr) | 43 (36–47) | 41 (25.5–46) |
| No. (%) of males | 39 (75) | 20 (80) |
| No. (%) of patients with HCV coinfectionb | 19 (39.6) | 7 (28) |
| CD4+ count (cells/mm3) | 274 (119–424) | 302 (171–521) |
| No. (%) of patients in risk group | ||
| IDUc | 19 (39.6) | 11 (44) |
| Sexual risk | 26 (54.2) | 9 (36) |
| Other | 3 (6.3) | 4 (16) |
| No. (%) of patients with stage C disease (according to CDC) | 8 (16.6) | 8 (32) |
| Plasma HIV-1 RNA load (log10 copies/ml) | 4.59 (4.15–4.98) | 3.86 (2.79–4.98) |
| ΔVL after MCT (log10 copies/ml)d | −1.16 (−0.66–−1.54) | −0.71 (−1.32–0.11) |
a
Values other than numbers with percentages are expressed as medians (IQR). VR, virological response. Differences between groups were analyzed using the Mann-Whitney U test, and P was >0.05 (not significant) in all cases.
b
PCR positive for hepatitis C virus.
c
Intravenous drug use.
d
ΔVL, viral load change.